Oto Revenue and Competitors
Estimated Revenue & Valuation
- Oto's estimated annual revenue is currently $4.3M per year.
- Oto's estimated revenue per employee is $189,000
Employee Data
- Oto has 23 Employees.
- Oto grew their employee count by -21% last year.
Oto's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | Software Engineer | Reveal Email/Phone |
Oto Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $28.1M | 104 | 12% | N/A | N/A |
#2 | $35.9M | 133 | 1% | N/A | N/A |
#3 | $74.3M | 250 | 5% | N/A | N/A |
#4 | N/A | 0 | N/A | N/A | N/A |
#5 | $24M | 89 | -19% | £8.2M | N/A |
#6 | $8.6M | 40 | -9% | N/A | N/A |
#7 | $15.3M | 63 | -14% | N/A | N/A |
#8 | $182.3M | 540 | 9% | N/A | N/A |
#9 | $182.3M | 540 | 14% | N/A | N/A |
#10 | $148.5M | 440 | 6% | N/A | N/A |
What Is Oto?
Oto builds digital therapeutics for tinnitus. There are 390 million people with intrusive tinnitus around the world. Our mission to help them, by providing science-based therapy, that is accessible to all.
keywords:N/AN/A
Total Funding
23
Number of Employees
$4.3M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oto News
Clinical benefit again observed for OTO-413 versus placebo for ... the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
He will be a tarting linebacker for the Crimson Tide to open up the 2022 season. Henry To'oto'o's Photo Gallery. Syndication: Tuscaloosa News.
Clinical benefit again observed for OTO-413 versus placebo for ... the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
He will be a tarting linebacker for the Crimson Tide to open up the 2022 season. Henry To'oto'o's Photo Gallery. Syndication: Tuscaloosa News.
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.3M | 23 | 10% | N/A |
#2 | $1.6M | 23 | -39% | N/A |
#3 | $2.3M | 23 | -4% | N/A |
#4 | $1.9M | 23 | 0% | N/A |
#5 | $5.2M | 23 | -12% | N/A |
